Cargando…
Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells
Antibody-drug conjugates (ADCs) are composed of an antibody linked to cytotoxic anticancer payloads. ADCs recognize tumor-specific cell surface antigens and are internalized into lysosomes where proteolytic enzymes release the cytotoxic payloads. Efflux transporters on plasma membrane that play a si...
Autores principales: | Liu-Kreyche, Peggy, Shen, Hong, Marino, Anthony M., Iyer, Ramaswamy A., Humphreys, W. Griffith, Lai, Yurong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650582/ https://www.ncbi.nlm.nih.gov/pubmed/31379564 http://dx.doi.org/10.3389/fphar.2019.00749 |
Ejemplares similares
-
Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload
por: Wang, Yanming, et al.
Publicado: (2017) -
Brentuximab Vedotin
Publicado: (2012) -
Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022) -
Monomethyl Auristatin E Grafted-Liposomes to Target Prostate Tumor Cell Lines
por: Abawi, Ariana, et al.
Publicado: (2021) -
Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates
por: Fu, Zhiwen, et al.
Publicado: (2023)